Ariad Announces Updated Findings from Pivotal Pace Trial of Ponatinib to Be Presented at Annual Meeting of American Society of Clinical Oncology

Published on Wednesday, 16 May 2012 18:07 Written by TradersHuddle Staff

CAMBRIDGE, Mass.-( Business Wire )-

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that updated clinical data from the pivotal PACE trial of its investigational, pan-BCR-ABL inhibitor, ponatinib, will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, June 1-5, 2012.

The updated findings from the PACE trial will be featured in an oral presentation on Monday, June 4, 2012 and will also be highlighted in a company-sponsored investor meeting to be webcast live from Chicago. This trial is being conducted in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblasatic leukemia (Ph + ALL) who are resistant or intolerant to either nilotinib or dasatinib, two currently available CML therapies, or those who have the T315I mutation of BCR-ABL for which no current treatments are known to be effective. The ASCO presentation will include at least six months of available response data from all patients enrolled in the trial and will form the basis of ARIAD’s regulatory filings for marketing approval of ponatinib in the U.S., Europe and other geographies.

The schedule and details for the oral presentation and investor meeting are below:

Oral Presentation of Updated Response Data from Pivotal Phase II PACE Trial
Title:				PACE: A Pivotal Phase II Trial of Ponatinib in Patients with CML and
				Ph+ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the
				T315I Mutation
Oral Session:				Leukemia, Myelodysplasia, and Transplantation
Date & Time:				Monday, June 4, 2012, 9:00 a.m. (CT)
Abstract No:				6503
Presenter:				Jorge E. Cortes, M.D. (The University of Texas MD Anderson Cancer Center)
Location:				E354a

Investor and Analyst Briefing and Webcast

A lunch meeting to review the updated clinical data from the pivotal PACE trial with research analysts and institutional investors will feature Jorge Cortes, M.D., Distinguished Professor for Leukemia Research, Deputy Chairman and Section Chief of the AML and CML programs at the University of Texas MD Anderson Cancer Center, and members from ARIAD management. Dr. Cortes has been an investigator in the Phase 1 and Phase 2 trials of ponatinib. This meeting will be webcast live along with slides and can be accessed by visiting the investor relations section of the Company’s website at http://investor.ariad.com or dialing: 888-396-2298 (domestic) or 617-847-8708 (international) and providing the passcode 10684197.

Date:						Monday, June 4, 2012
Time:						12:00 p.m. to 1:00 p.m. (CT)
Location:						Chicago Hilton, Buckingham Room on lobby level

To attend the meeting, please RSVP to This e-mail address is being protected from spambots. You need JavaScript enabled to view it. by Wednesday, May 30, 2012.

A replay of the investor event will be available on the ARIAD website approximately three hours after the presentation and will be archived on the site for four weeks. To ensure a timely connection to the live webcast, participants should log onto the webcast at least 15 minutes prior to the scheduled start time.

About ARIAD

ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD’s approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter.

ARIAD Pharmaceuticals, Inc.For InvestorsMaria E. Cantor, 617-621-2208Maria.cantor@ariad.comorFor MediaLynn Granito, This e-mail address is being protected from spambots. You need JavaScript enabled to view it.